What is missing from descriptions of treatment in trials and reviews?
Top Cited Papers
- 26 June 2008
- Vol. 336 (7659), 1472-1474
- https://doi.org/10.1136/bmj.39590.732037.47
Abstract
Why are full descriptions of treatment important?The uptake of positive findings from trials is often slow and sometimes negligible.3 Reasons for this slow uptake include clinicians not becoming aware of the results, perceiving the results as either invalid or not relevant to their patients, or simply not remembering to use the treatment.4 5 An additional barrier, which has received less attention, is clinicians’ ability to carry out the treatment on the basis of the information provided in the published reports. For example, after receiving numerous requests for additional details from doctors and patients, the author of a randomised trial on graded exercise for chronic fatigue syndrome6 subsequently published a supplementary article with a more detailed “prescription.”7 Similarly, it is not possible to set upa stroke unit, offer low fat diets, or give smoking cessation advice without sufficient details on the components that were planned and delivered.8This publication has 13 references indexed in Scilit:
- Reporting Implementation in Randomized Trials: Proposed Additions to the Consolidated Standards of Reporting Trials StatementAmerican Journal of Public Health, 2007
- Graphical method for depicting randomised trials of complex interventionsBMJ, 2007
- Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic reviewThe Medical Journal of Australia, 2006
- Exercise prescription for individuals with chronic fatigue syndromeThe Medical Journal of Australia, 2005
- The paths from research to improved health outcomes.2005
- Empirical Evidence for Selective Reporting of Outcomes in Randomized TrialsJAMA, 2004
- Implementation of evidence-based medicine: evaluation of the Promoting Action on Clinical Effectiveness programmeJournal of Health Services Research & Policy, 2001
- Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statementThe Lancet, 1999
- The Awareness-to-Adherence Model of the Steps to Clinical Guideline ComplianceMedical Care, 1996
- Improving the quality of reporting of randomized controlled trials. The CONSORT statementJAMA, 1996